tbuckley/cabot-search huggingface dataset:
Contents
Authors: P Burra, F Tacke, V Ratziu, S Zeuzem, B Sangro, P Angeli, J Flemming, M Velez, A Avanceña, N Miller, S Uttal, D Hutton, J Mellinger, Z.-Y Ding, G.-X Li, L Chen, C Shu, J Song, W Wang, Y.-W Wang, Q Chen, G.-N Jin, T.-T Liu, J.-N Liang, P Zhu, W Zhu, Y Li, B.-H Zhang, H Feng, W.-G Zhang, Z.-Y Yin, W.-K Yu, Y Yang, H.-Q Zhang, Z.-P Tang, H Wang, J.-B Hu, J.-H Liu, P Yin, X.-P Chen, J Chen, B Liu, X Tang, X Zheng, J Lu, L Zhang, D Candotti, Y Fu, J.-P Allain, C Li, L Li, T Li, S Sridhar, J Situ, J.-P Cai, C.-Y Yip, S Wu, -X Zhang, L Wen, -S Chew, W.-M Chan, -S Poon, -W Chan, -C Tsang, H Chen, N.-S Xia, K.-Y Yuen, E De Martin, A Coilly, O Chazouillères, O Roux, J.-M Peron, P Houssel-Debry, F Artru, C Silvain, I Ollivier-Hourmand, C Duvoux, A Heurgue, S Barge, N Ganne-Carrié, G.-P Pageaux, C Besch, M Bourlière, H Fontaine, V De Ledinghen, J Dumortier, F Conti, S Radenne, M Debette-Gratien, O Goria, F Durand, P Potier, V Di Martino, N Reboux, P Ichai, M Sebagh, P Mathurin, H Agostini, D Samuel, J.-C Duclos-Vallée, T Marjot, G Buescher, M Sebode, E Barnes, A Barritt, M Armstrong, L Baldelli, J Kennedy, C Mercer, A.-K Ozga, C Casar, C Schramm, A Cirrhosis, G Moon, A Webb, J Schattenberg, A Pares, K Kowdley, M Heneghan, S Caldwell, D Pratt, A Bonder, G Hirschfield, C Levy, J Vierling, D Jones, A Tailleux, B Staels, S Megnien, R Hanf, D Magrez, P Birman, V Luketic, M Abdallah, Y.-F Kuo, S Asrani, R Wong, A Ahmed, P Kwo, N Terrault, P Kamath, R Jalan, A Singal, D Bettinger, L Sturm, L Pfaff, F Hahn, R Kloeckner, L Volkwein, M Praktiknjo, Y Lv, G Han, J Huber, T Boettler, M Reincke, C Klinger, K Caca, H Heinzow, L Seifert, K Weiss, C Rupp, F Piecha, J Kluwe, A Zipprich, H Luxenburger, C Neumann-Haefelin, A Schmidt, C Jansen, C Meyer, F Uschner, M Brol, J Trebicka, M Rössle, R Thimme, M Schultheiss, C Raggi, M Taddei, E Sacco, N Navari, M Correnti, B Piombanti, M Pastore, C Campani, E Pranzini, J Iorio, G Lori, T Lottini, C Peano, J Cibella, M Lewinska, J Andersen, L Di Tommaso, L Viganò, G Maira, S Madiai, M Ramazzotti, I Orlandi, A Arcangeli, F Marra, J Kellum, M Nadim, R Morikawa, N Nakamoto, T Amiya, P.-S Chu, Y Koda, T Teratani, T Suzuki, Y Kurebayashi, A Ueno, N Taniki, K Miyamoto, A Yamaguchi, S Shiba, T Katayama, K Yoshida, Y Takada, R Ishihara, H Ebinuma, M Sakamoto, T Kanai, S.-T Cheng, J.-L Hu, J.-H Ren, H.-B Yu, S Zhong, V Wong, B Kwan Law, W.-X Chen, H.-M Xu, Z.-Z Zhang, X.-F Cai, Y Hu, W.- L Zhang, Q.-X Long, F Ren, H.-Z Zhou, A.-L Huang, J Howell, A Pedrana, S Schroeder, N Scott, L Aufegger, R Atun, R Baptista-Leite, G Hirnschall, E 't Hoen, S Hutchinson, J Lazarus, L Olufunmilayo, R Peck, M Sharma, A Sohn, A Thompson, M Thursz, D Wilson, M Hellard, S.-Y Cai, D Yu, C Soroka, J Wang, J Boyer, D Chand, F Mohr, H Mcmillan, F Tukov, K Montgomery, A Kleyn, R Sun, S Tauscher-Wisniewski, P Kaufmann, G Kullak-Ublick, A Moon, J Cook, S Abd-Elsalam, C Aloman, E Pose, E Brenner, T Cargill, M.-A Catana, R Dhanasekaran, A Eshraghian, I García-Juárez, U Gill, P Jones, A Marshall, C Matthews, G Mells, P Perumalswami, E Avitabile, X Qi, F Su, N Ufere, Y Wong, M.-H Zheng, G Webb
Journal: Journal of Hepatology (2021)
"Poor Carrasquilla."
Authors: Albert S. Ashmead
Journal: JAMA (1898)

New York, January 31, 1897. <h3>To the Editor:</h3> —"A discussion of serum treatment followed, in which poor Carrasquilla suffered. Excepting by his own countrymen, no results were reported from the use of his discovery, and the Germans, the English and others came down in full force to deny not only the usefulness but to argue dangers from its employment.... Poor Carrasquilla, to have traveled so far and yet found so little at the end of his journey."—<i>New Orleans Medical and Surgical Journal</i>, December, 1897, Special Correspondence on "The Berlin Leprosy Conference." When the lion was sick, every beast whom he had wronged in his life came to have a blow at him; and when the ass had for some time contemplated this spectacle, with growing courage he actually went and tried a kick of his own. Such a thing happens frequently among men; but, whoever plays the donkey in
FDG PET/CT of Primary Breast Lymphoma in a Man
Authors: Pengcheng Ran, Hui Li, Yongzhen Hu, Miao Chen, Aisheng Dong
Journal: Clinical Nuclear Medicine (2022)

Primary lymphoma of the male breast is extremely rare. We describe FDG PET/CT findings in a man with primary breast lymphoma in his right breast. The breast tumor showed intense FDG uptake mimicking breast carcinoma.
Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes
Authors: Julia Ware, Janet M. Allen, Charlotte K. Boughton, Malgorzata E. Wilinska, Sara Hartnell, Ajay Thankamony, Carine de Beaufort, Ulrike Schierloh, Elke Fröhlich-Reiterer, Julia K. Mader, Thomas M. Kapellen, Birgit Rami-Merhar, Martin Tauschmann, Katrin Nagl, Sabine E. Hofer, Fiona M. Campbell, James Yong, Korey K. Hood, Julia Lawton, Stephane Roze, Judy Sibayan, Laura E. Bocchino, Craig Kollman, Roman Hovorka
Journal: New England Journal of Medicine (2022)

The possible advantage of hybrid closed-loop therapy (i.e., artificial pancreas) over sensor-augmented pump therapy in very young children with type 1 diabetes is unclear.In this multicenter, randomized, crossover trial, we recruited children 1 to 7 years of age with type 1 diabetes who were receiving insulin-pump therapy at seven centers across Austria, Germany, Luxembourg, and the United Kingdom. Participants received treatment in two 16-week periods, in random order, in which the closed-loop system was compared with sensor-augmented pump therapy (control). The primary end point was the between-treatment difference in the percentage of time that the sensor glucose measurement was in the target range (70 to 180 mg per deciliter) during each 16-week period. The analysis was conducted according to the intention-to-treat principle. Key secondary end points included the percentage of time spent in a hyperglycemic state (glucose level, >180 mg per deciliter), the glycated hemoglobin level, the mean sensor glucose level, and the percentage of time spent in a hypoglycemic state (glucose level, <70 mg per deciliter). Safety was assessed.A total of 74 participants underwent randomization. The mean (±SD) age of the participants was 5.6±1.6 years, and the baseline glycated hemoglobin level was 7.3±0.7%. The percentage of time with the glucose level in the target range was 8.7 percentage points (95% confidence interval [CI], 7.4 to 9.9) higher during the closed-loop period than during the control period (P<0.001). The mean adjusted difference (closed-loop minus control) in the percentage of time spent in a hyperglycemic state was -8.5 percentage points (95% CI, -9.9 to -7.1), the difference in the glycated hemoglobin level was -0.4 percentage points (95% CI, -0.5 to -0.3), and the difference in the mean sensor glucose level was -12.3 mg per deciliter (95% CI, -14.8 to -9.8) (P<0.001 for all comparisons). The time spent in a hypoglycemic state was similar with the two treatments (P = 0.74). The median time spent in the closed-loop mode was 95% (interquartile range, 92 to 97) over the 16-week closed-loop period. One serious adverse event of severe hypoglycemia occurred during the closed-loop period. One serious adverse event that was deemed to be unrelated to treatment occurred.A hybrid closed-loop system significantly improved glycemic control in very young children with type 1 diabetes, without increasing the time spent in hypoglycemia. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT03784027.).
Response to Comment on Shih et al. Increased Incidence of Pediatric Type 1 Diabetes With Novel Association With Coxsackievirus A Species in Young Children but Declined Incidence in Adolescents in Taiwan. Diabetes Care 2021;44:1579–1585
Authors: Wei-Liang Shih, Yi-Ching Tung, Luan-Yin Chang
Journal: Diabetes Care (2021)
Microbes in the gut relate to melanoma severity
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Vitali et al. Br J Dermatol 2022; 186:106–116. Melanoma is a skin cancer arising from melanocytes (the cells producing melanin, a pigment determining the colour of our skin that is able to protect us against ultraviolet radiation damage). It is a serious type of cancer, causing the greatest number of skin cancer-related deaths worldwide. Microorganisms (fungi, yeasts and bacteria) living in association with our body are termed ‘microbiota’. We have evolved to live in cooperation (symbiosis) with our microbiota. Knowing already about the ability of the gut microbiota to interact with the host immune system, and also knowing that melanoma is a type of cancer that strongly activates the immune system, we conducted this study to see if the microbiota living in patient’s gut could be linked to the degree of the severity of their disease. We studied the gut ecosystem using an approach called next-generation sequencing to identify all the microbes. The study was conducted in Italy, involving patients with melanoma and healthy control participants. Our results showed that patients with melanoma have a different gut microbiota than healthy controls. Also, that in the patients with melanoma both the bacterial and fungi community profiles are linked to the severity of the disease. We conclude that the microbiota in early-stage melanoma changes along with the severity of the disease. Our results suggest promising future developments in early melanoma research. Linked Article: Vitali et al. Br J Dermatol 2022; 186:106–116.
PARIS
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influence of long term treatment with carvedilol and metoprolol on $beta;-adrenergic signal transduction and intracellular calcium handling in cardiomyopathic hamsters Karsten Filzmaier, Ulrich Schotten, Carsten Hoeper, Eckard Picht, Mireille Van Helden, Bernd Koenigs, Miriam Vogel, Ruediger Blindt, Peter Hanrath. University Hospital Aachen, Aachen, Germany
Journal: Journal of the American College of Cardiology (2001)
Cohort studies
Authors: P. Sedgwick
Journal: BMJ (2010)

Researchers investigated whether increased body mass index was a risk factor for prostate cancer.1 Data from a prospective cohort study known as the Health Professionals Follow-Up Study was used.2 In this study, 51 529 American health professionals aged between 40 and 75 years responded to a postal questionnaire. The health professionals were recruited in 1986 and self reported that they were free of prostate cancer at the start of the study. Participants were then followed up at regular intervals until 1994. Which of the following statements, if any, are true?
Coronary sinus anatomy in patients with epicardial posteroseptal and left posterior accessory pathways Yingxian Sun, Mauricio S. Arruda, Karen J. Beckman, Hiroshi Nakagawa, Peter Spector, Nayyar Shah, James Calame, Daniel Lustgarten, Arun Rao, Ralph Lazzara, Warren M. Jackman. University of Oklahoma, Oklahoma City, OK
Journal: Journal of the American College of Cardiology (2001)
Errors in Table 1
Journal: JAMA Network Open (2022)

Sha Huang, BS; Yang Guo, PhD; Zhong-Wu Li, PhD; Guanghou Shui, PhD; He Tian, PhD; Bo-Wen Li, MS; Gaohaer Kadeerhan, PhD; Zhe-Xuan Li, PhD; Xue Li, BS; Yang Zhang, PhD; Tong Zhou, BS; Wei-Cheng You, MD; Kai-Feng Pan, PhD; Wen-Qing Li, PhD
Radioembolization with chemotherapy for liver-dominant colorectal cancer: Analysis of patient subgroups in the EPOCH trial.
Authors: William Proctor Harris, Mary Frances Mulcahy, Riad Salem
Journal: Journal of Clinical Oncology (2022)

115 Background: The EPOCH trial evaluated potential benefit of second-line transarterial radioembolization (TARE) plus chemotherapy compared to chemotherapy alone in patients with liver-dominant metastatic colorectal disease (mCRC). Presented here are additional results from EPOCH of depth and duration of response (DoR), and progression-free survival (PFS) and hepatic progression-free survival (hPFS) subgroup analyses. Methods: EPOCH was a 1:1 randomized, open-label, global, multicenter phase 3 trial of second-line chemotherapy for liver-dominant mCRC comparing outcomes from chemotherapy with or without unilobar or same-day bilobar TARE treatment using glass microspheres. Primary study endpoints were PFS and hPFS. Pre-specified subgroup analyses of PFS and hPFS were performed. PFS, hPFS, DoR for patients with objective response, and depth of response (percent change from baseline to nadir in sum of longest diameters of target lesions) were based on blinded, independent central review using RECIST 1.1. The use of TheraSphere in the trial in the USA was under Investigational Device Exemption from FDA. Results: Both primary endpoints of PFS (HR = 0.69, 95% CI: 0.54, 0.88; 1-sided p=0.0013) and hPFS (HR = 0.59, 95% CI: 0.46, 0.77; 1-sided p&lt;0.0001) were met in the EPOCH study. Median DoR in the 73 responders of the TARE arm was numerically longer, with 7.2 months by Kaplan-Meier analysis; in the 45 responders of the chemotherapy only arm, 6.6 months (HR = 0.79, 95% CI: 0.48, 1.30; 1-sided p = 0.178). Mean depth of response across all patients in the TARE arm with data available (N=196) was -25.6%, compared to -13.0% in the chemotherapy only arm (N=182; mean difference -12.6 percentage points; 95% CI: -18.9, -6.3; 1-sided p = 0.0001). Key subgroups of interest which showed improved PFS and/or hPFS in the TARE arm (ie, 95% CI for the HR entirely below 1) are as follows: Conclusions: These data suggest that liver-dominant mCRC patients in this trial benefitted in second-line treatment from a combination of TARE plus chemotherapy based upon improved PFS and hPFS over the full set of patients and in a number of subgroups. The addition of TARE to chemotherapy improves depth of response compared to chemotherapy alone. Clinical trial information: NCT01483027. [Table: see text]
Gall stones and treatment with octreotide for acromegaly.
Journal: BMJ (1989)

show increased direct catabolism of VLDL apo- lipoprotein B without conversion to low density lipoprotein resulting in lower concentrations of total and low density lipoprotein cholesterol than in white people.Whether such compensatory mechanisms operate in other ethnic groups is not known, but the lipid/lipoprotein patterns found in Asians suggest that they do not.In Afro-Caribbean people (who currently have low rates of coronary disease) similar patterns to those in the Pima Indians are found, but in black Americans (in whom insulin resistance and high rates of coronary disease and diabetes now occur) the lipid profile is closer to that of white Americans.56Contrary to Professor Jarrett's negative view of current hypotheses, there is much in favour of the C peptide-insulin-atheroma link, particularly if data from in vitro experiments on insulin-like growth factors and homologous peptides are in- cluded.Refinements and novel approaches to these ethnic differences, rather than the guillotine, are required.Vive la difference!
Contact‐Free Remote Manipulation of Hydrogel Properties Using Light‐Triggerable Nanoparticles: A Materials Science Perspective for Biomedical Applications
Authors: Cho‐E Choi, Aishik Chakraborty, Ali Coyle, Yasmeen Shamiya, Arghya Paul
Journal: Advanced Healthcare Materials (2022)

Considerable progress has been made in synthesizing "intelligent", biodegradable hydrogels that undergo rapid changes in physicochemical properties once exposed to external stimuli. These advantageous properties of stimulus-triggered materials make them highly appealing to diverse biomedical applications. Of late, research on the incorporation of light-triggered nanoparticles (NPs) into polymeric hydrogel networks has gained momentum due to their ability to remotely tune hydrogel properties using facile, contact-free approaches, such as adjustment of wavelength and intensity of light source. These multi-functional NPs, in combination with tissue-mimicking hydrogels, are increasingly being used for on-demand drug release, preparing diagnostic kits, and fabricating smart scaffolds. Here, the authors discuss the atomic behavior of different NPs in the presence of light, and critically review the mechanisms by which NPs convert light stimuli into heat energy. Then, they explain how these NPs impact the mechanical properties and rheological behavior of NPs-impregnated hydrogels. Understanding the rheological behavior of nanocomposite hydrogels using different sophisticated strategies, including computer-assisted machine learning, is critical for designing the next generation of drug delivery systems. Next, they highlight the salient strategies that have been used to apply light-induced nanocomposites for diverse biomedical applications and provide an outlook for the further improvement of these NPs-driven light-responsive hydrogels.
Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study
Authors: Bhagirathbhai Dholaria, Myriam Labopin, Emanuele Angelucci, Fabio Ciceri, José Luis Díez-Martín, Benedetto Bruno, Simona Sica, Yener Koc, Zafer Gulbas, Christoph Schmid, Didier Blaise, Angelo Michele Carella, Giuseppe Visani, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Journal: Blood (2019)
The direction of medical education today
Authors: L. L. Terry
Journal: JAMA (1966)

Throughout the history of our country, medical education has changed with the times. It has adapted itself to new demands and has now reached so high a level of excellence that students and physicians and biomedical scientists from all over the world look to us for training and leadership. It might seem that we could say with complacency, "Let us let well enough alone and continue as we have been." Yet rarely in our history has there been such questioning of the rightness of the path on which we find ourselves. Rarely has there been such genuine desire by medical educators and the medical profession to reexamine our plans, and we seek to make new estimates of the value of our goals and new judgments of how we may achieve them. In the past, we have adapted as changing conditions required. From this flexibility, much of our present excellence stems,
The Royal Colleges and the Women.
Authors: None J. S. C.
Journal: JAMA (1896)

<h3>To the Editor:</h3> — The recent action of the Royal Colleges of Physicians and Surgeons, England, in declining, by a narrow vote, to grant women their diplomas, is indicative both of the remaining prejudice against women doctors and the progress of their efforts for complete recognition by the profession. The two chief arguments against them, aside from natural unfitness, were that they commonly entered the profession from improper motives, and that they had contributed nothing toward its advance. It is thus quite evident that some of our professional brethren across the water, have been expecting too much from the "gentler sex," for the very same arguments will apply equally well to not a few of the masculine denomination. Also the fact seems to have been overlooked that the "new" woman is still comparatively new and has hardly had time to evolve that increase of brain and the desexing process which
42P Radiation induced pneumonitis in the era of the COVID-19 pandemic: Artificial intelligence for differential diagnosis
Authors: S. Ramella, C.C. Quattrocchi, E. Ippolito, F.M. Giordano, C. Greco, C.A. Mallio, B. Santo, P. D'Alessio, M. Fiore, R.M. D'Angelillo, B. Beomonte Zobel
Journal: Journal of Thoracic Oncology (2021)
Impaired fibrinolytic capacity in rheumatic and nonrheumatic atrial fibrillation Enver Atalar, Tayfun Acil, Kudret Aytemir, �brahim Haznedaroglu, Necla Ozer, Serdar Aksoyek, Kenan �v�n�, S�rr� Kes, Ferhan Ozmen. Hacettepe University School of Medicine Department of Cardiology, Ankara, Turkey, Hacettepe University School of Medicine Hematology Department, Ankara, Turkey
Journal: Journal of the American College of Cardiology (2001)
The putative $beta;4-adrenoceptor-mediated positive modulation on cardiac L-type calcium current: Normal versus congestive heart failure Zhu-Shan Zhang, Heng-Jie Cheng, Tomohiko Ukai, Hideo Tachibana, Akihiko Igawa, Che-Ping Cheng. Wake Forest University School of Medicine, Winston-Salem, NC
Journal: Journal of the American College of Cardiology (2001)
Heparin
Authors: John A. Oates, Alastair J.J. Wood, Jack Hirsh
Journal: New England Journal of Medicine (1991)

HEPARIN was discovered in 1916 by McLean,1 who as a medical student was looking for a coagulant in the liver. In 1939, Brinkhous and associates2 demonstrated that the anticoagulant activity of heparin requires a plasma cofactor (that they called heparin cofactor). In 1968, Abildgaard3 renamed the substance antithrombin III, and the mechanism of interaction between antithrombin III and heparin was elucidated in the 1970s.4 5 6 7 The active center serine of thrombin and other coagulation enzymes is inhibited by an arginine reactive center of the antithrombin III molecule. Heparin binds to lysine sites on antithrombin III and produces a conformational change at . . .